Evaluating TGRX-678 for patients with advanced Chronic Myelogenous Leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-arm, open-label Phase I trial designed to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of TGRX-678 in patients with refractory or advanced Chronic Myelogenous Leukemia (CML) who have failed or are intolerant to TKI treatments. The study will involve dose escalation and cohort expansion to determine the recommended dose for further trials. Participants will be monitored for adverse events and changes in disease markers to evaluate the drug's effectiveness. This is the first trial of TGRX-678 conducted in the US.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Willing to participate in the study with informed consent;
* At least 18 years of age at the time of screening;
* Any sex;
* Diagnosis of CML-CPduring the screening period;
* Intolerant or resistant to TKI treatments;
* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2;
* Adequate Absolute neutrophil count (ANC), hemoglobin and platelets levels;
* Adequate renal and liver function;
* Normal corrected QT (QTcF) interval as indicated by electrocardiogram (ECG) screening results;
* Negative blood pregnancy test results for female patients of childbearing potential.
* Willing to take highly effective contraceptive measures throughout the trial and for 6 months after last dose of investigational drug for female subjects of child-bearing potential or male subject with female partner of child-bearing potential.

Exclusion Criteria:

* Exposure to other antineoplastic therapies prior to study enrollment;
* Exposure to other investigational agent(s) within 14 days of initiating TGRX-678 therapy;
* Ongoing toxicity from prior therapy greater than grade 1 by CTCAE v. 3 (except alopecia);
* Hematopoietic cell transplantation \< 60 days prior to the first dose;
* Evidence of graft versus host disease (GVHD), whether or not requiring immunosuppressive therapy;
* Concomitant immunosuppressive therapy (other than short-term corticosteroid treatment);
* Exposure to drugs related to torsade de pointes;
* Cytological or pathological diagnosis of active central nervous system disorder;
* Significant or uncontrolled cardiovascular diseases as defined in the full clinical protocol;
* Having long QT syndrome, or with family history of idiopathic sudden death or congenital long QT syndrome;
* Uncontrolled hypertension;
* Receipt of Traditional Chinese medication or herbal preparations indicated for anti-cancer purposes within 2 weeks prior to the first dose;
* Severe hemorrhagic disorders unrelated to CML;
* History of pancreatitis;
* History of excessive alcohol use;
* History of elevation in amylase or lipase within 1 year;
* Have Grade 2 or worse interstitial lung disease or interstitial pneumonitis within 4 weeks prior to Screening;
* Uncontrolled hypertriglyceridemia;
* Malabsorption syndrome or other illness that could affect oral absorption.
* Diagnosis of another primary malignancy in the past 3 years;
* Reception of major surgery within 14 days prior to the first dose;
* Active infections that require systemic treatment or other severe infections within 14 days prior to enrollment;
* Known human immunodeficiency virus (HIV) positive; acute or chronic liver disease (including chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections);
* Have received or will receive a COVID-19 vaccine within 14 days of study enrollment;
* Have a positive reverse transcriptase polymerase chain reaction (RT-PCR) test result for SARS-CoV-2 within 2 weeks prior to Screening;
* Pregnant or breastfeeding female;
* Female patient of child-bearing potential or male patient who have female partners of child-bearing potential that is unable or unwilling to take highly effective contraceptive measures during the trial and for 6 months after last dose of investigational drug;
* Significant organ dysfunction that could compromise the patient's safety or the evaluation of the drug's safety in the opinion of the investigator or the medical monitor;
* Any condition makes participation in this trial inappropriate in the opinion of the investigator or medical monitor;

Where it's running

• The University of Texas MD Anderson Cancer Center
  Houston, Texas, United States Recruiting
• Fred Hutchinson Cancer Center
  Seattle, Washington, United States Recruiting

Study contacts

• Principal investigator: Elias Jabbour — M.D. Anderson Cancer Center
• Study coordinator: Xinyi Zhu
• Email: xinyi.zhu@tjrbiosciences.com
• Phone: 86-13061651609

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Asciminib for children and teens with Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase

  This study will try asciminib as a treatment for children aged 1 to under 18 with Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase, including newly diagnosed patients and those who are resistant or intolerant to prior TKIs, with or without the T315I mutation.

  Recruiting at 39 sites Phase 2 Novartis · Chicago, Illinois and 38 other locations · NCT07354074

• Study of crushed venetoclax tablets dissolved in liquid for pediatric patients

  This study tests if crushing venetoclax tablets and mixing them with liquid helps children with blood cancers absorb the medication better and stay safe while taking it.

  Recruiting at 5 sites Children's Hospital Medical Center, Cincinnati · Aurora, Colorado and 5 other locations · NCT06131801

• Stem cell transplant using a specific preparative regimen for blood cancers

  This study is testing a new way to prepare for a stem cell transplant using a special combination of medications and radiation to see if it helps people with acute leukemia who are in remission.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT05805605

• Comparing T Cell Depletion Methods for Blood Cancer Treatment

  This study is testing different ways to prevent complications after a stem cell transplant for blood cancer to see which method helps patients stay healthy and cancer-free longer.

  Recruiting at 17 sites Phase 2 University of Birmingham · Cardiff, Wales and 16 other locations · NCT04888741

• Long-term safety treatment for chronic myelogenous leukemia patients

  This study is testing the long-term safety of a medication called asciminib for patients with chronic myelogenous leukemia who have already been part of another study.

  Recruiting at 61 sites Phase 4 Novartis · Ann Arbor, Michigan and 87 other locations · NCT04877522

• Hematopoietic stem cell transplant for blood cancers

  This study is testing two different ways of doing stem cell transplants for people with blood cancers to see which method works better and is safer.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT03314974

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.